HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis

Circulation

Volumn 109, Issue 21, 2004, Pages 2560-2565

  Merx, Marc W ^a,c   Liehn, Elisa A ^a   Janssens, Uwe ^a   Lütticken, Rudolf ^a   Schrader, Jürgen ^b   Hanrath, Peter ^a   Weber, Christian ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Hemodynamics; Inflammation; Leukocytes; Sepsis; Statins

Indexed keywords

BRADYKININ; DOBUTAMINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG MECHANISM; ENZYME ACTIVATION; HEART FUNCTION; IMMUNOMODULATION; INFLAMMATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME;

ANIMALS; AORTA; BRADYKININ; CARDIAC OUTPUT; CARDIOTONIC AGENTS; CECAL DISEASES; CELL ADHESION; CELLS, CULTURED; CORONARY CIRCULATION; DOBUTAMINE; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; HEMODYNAMIC PROCESSES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL PERFORATION; LEUKOCYTES; LIGATION; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL CONTRACTION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; SEPSIS; SIMVASTATIN;

EID: 2642553075     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000129774.09737.5B     Document Type: Article

References (27)

1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-150.
2. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. 2003;9:517-524.
3. Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-658.
4. Annane D. Corticosteroids for septic shock. Crit Care Med. 2001;29: S117-S120.
5. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
6. Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med. 1996;334:1697-1702.
7. Fisher CJ Jr, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study group. Crit Care Med. 1994;22:12-21.
8. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 1991;324:429-436.
9. Bernard GR, Wheeler AP, Russel JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med. 1997;336:912-918.
10. Ulloa L, Ochani M, Yang H, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A. 2002;99:12351-12356.
11. Bernhagen J, Calandra T, Mitchell RA. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993;365:756-759.
12. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399-1402.
13. Pruefer D, Makowski J, Schnell M, et al. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha toxin. Circulation. 2003;106:2104-2110.
14. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266-24271.
15. Merx MW, Flogel U, Stumpe T, et al. Myoglobin facilitates oxygen diffusion. FASEB J. 2001;15:1077-1079.
16. Heger J, Godecke A, Flogel U, et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res. 2002;90:93-99.
17. Ostermann G, Weber KS, Zernecke A, et al. JAM-1 is a ligand of the beta (2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunology. 2002;3:151-158.
18. Baltus T, Weber KS, Johnson Z, et al. Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood. 2003;102:1985-1988.
19. Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock. 1998;9:1-11.
20. Janssens U. Septic cardiovascular diseases. Dtsch Med Wochenschr. 2003;128:803-809.
21. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068-2101.
22. Rajavashith TB, Andalibi AS, Territo MC. Induction of endothelial cell expression of granulocyte and macrophage colony stimulation factors by modified low-density lipoprotein. Nature. 1990;344:254-257.
23. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMF-CoA reductase. Pharmacol Res. 1995;31:9-27.
24. Kurakata S, Kada M, Shimada Y, et al. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology. 1996;34:51-61.
25. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000;80:1095-1100.
26. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687-692.
27. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212-1217.